Myoclonus clinical trials
The registry lists 20 studies for Myoclonus across more than 10 countries. 6 are recruiting or about to start. 11 of them are mainly about Myoclonus (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Myoclonus studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Neurological Disorders and Stroke (NINDS) (5) · Boston Children's Hospital (3) · Yangzhou University (1) · National Human Genome Research Institute (NHGRI) (1) · Tang-Du Hospital (1) · Massachusetts Eye and Ear Infirmary (1) · UCB Pharma (1) · Rawalpindi Medical College (1)
What is being tested here
Drugs under test in Myoclonus studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Who these studies take
Of the 6 Myoclonus studies recruiting now, 3 (50%) set no upper age limit and 2 (33%) stop at 75 or younger. 6 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (17%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 6 (100%) | 6 (100%) |
| 18 | 6 (100%) | 6 (100%) |
| 30 | 5 (83%) | 5 (83%) |
| 40 | 4 (67%) | 4 (67%) |
| 50 | 4 (67%) | 4 (67%) |
| 65 | 4 (67%) | 4 (67%) |
| 75 | 4 (67%) | 4 (67%) |
| 85 | 4 (67%) | 4 (67%) |
Across all 20 studies, recruiting or not: 40% stop at 75 or younger and 30% at 65; 80% take children; 0% are for women only and 0% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- Natural History of Glycosphingolipid Storage Disorders and Glycoprotein DisordersRecruitingNCT000299651 country
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia SyndromesRecruitingNCT065856051 country
- Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)RecruitingNCT065939511 country
- Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated DystoniaRecruitingNCT05317390Not applicable1 country
- Registry and Natural History of Epilepsy-Dyskinesia SyndromesRecruitingNCT069677271 country
- High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)CompletedNCT07285369Not applicable1 country
- Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsCompletedNCT00368251Phase 38 countries
- Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate InjectionStatus unknownNCT05754762Not applicable
- Effect of Pretreatment of Lignocaine Versus Midazolam in Prevention of Etomidate Induced Myoclonus.CompletedNCT04921046Phase 4
- Electrophysiological Characteristics and Anatomical Differentiation of Epileptic and Non-epileptic Myoclonus.CompletedNCT042354521 country
- OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher DiseaseCompletedNCT00041535Phase 22 countries
- Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce MyoclonusStatus unknownNCT02518789Phase 4
- Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and AdultsCompletedNCT00357669Phase 37 countries
- Pilot Efficacy Study of T2000 in Myoclonus DystoniaTerminatedNCT00506012Phase 21 country
- Effectiveness of Rituximab in Pediatric OMS Patients.CompletedNCT00244361Phase 1/21 country
- Effect of Levetiracetam on Brain ExcitabilityCompletedNCT000061911 country
- Genotype/Phenotype Correlation of Movement Disorders and Other Neurological DiseasesCompletedNCT000016671 country
- Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic StimulationCompletedNCT00001663Phase 11 country
- Ketogenic Diet in Lafora DiseaseCompletedNCT000071241 country